Close Menu

CHICAGO (GenomeWeb) – Researchers are on the hunt for germline or somatic risk variants that might serve as markers for predicting immune-related adverse events (irAEs) in individuals treated with immune checkpoint blockade-based immunotherapy.

At the American Society of Clinical Oncology annual meeting here on Friday, Cleveland Clinic medical oncologist Vamsidhar Velcheti touched on the spectrum of toxicity events that are being reported as individuals with cancer are treated with drugs designed to tinker with the immune system.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.